Lindis Bloodcare is an innovative medical technology company based in Hennigsdorf, specializing in the development of safe and advanced blood management solutions for oncological surgeries. At the center is the medical product CATUVAB®, which works with a patented trifunctional antibody technology (ABCR technology) to selectively remove tumor cells from the blood of cancer patients. This enables the safe retransfusion of the patient's own blood during surgical procedures, thereby significantly reducing the risks of allogeneic blood transfusions, such as immune reactions and infection transmissions[1][2][5].
The main mission of Lindis Bloodcare is to sustainably improve the safety and effectiveness of blood transfusions during complex tumor surgeries, thereby setting new standards in oncological surgery. The company pursues the values of innovation, patient safety and clinical excellence. Through the development of CATUVAB®, they not only want to increase patient well-being, but also reduce the dependence on scarce blood donation resources[1][2][5].
Lindis Bloodcare was founded in 2018, but is deeply embedded in the bioscience expertise of its founders, including Dr. Horst Lindhofer (developer of the first trifunctional antibody) and Dr. Franzpeter Bracht (experienced life science manager). The platform technology enables the use of the antibody-filter combination in various clinical indications. As part of a large-scale multicenter clinical trial (REMOVE study with 130 patients), important milestones for the certification of the product were achieved in 2023[1][2][3][5].
Sustainability plays a significant role at Lindis Bloodcare, as the company not only minimizes risks for patients by avoiding allogeneic blood transfusions, but also pursues a valuable ecological and ethical goal: the resource-saving use of vital blood reserves. This relieves the already limited donor blood supply and contributes to a responsible use of medical resources[2][5].
Financially, Lindis Bloodcare is supported by well-known investors such as Brandenburg Kapital and the High-Tech Gründerfonds, which has enabled the research, certification and market launch of CATUVAB®[3][4].
In summary, Lindis Bloodcare is characterized by a unique combination of biotechnological innovation, clinical relevance and sustainable healthcare. The development of CATUVAB® revolutionizes blood management in cancer surgery, promotes patient safety and sets new standards in the handling of transfusions.
